Abstract
We identified four novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs), GRL-078, -079, -077, and -058, containing an alkylamine at the C-5 position of P2 tetrahydropyrano-tetrahydrofuran (Tp-THF) and a P2' cyclopropyl (Cp) (or isopropyl)-aminobenzothiazole (Abt) moiety. Their 50% effective concentrations (EC50s) were 2.5 to 30 nM against wild-type HIV-1NL4-3, 0.3 to 6.7 nM against HIV-2EHO, and 0.9 to 90 nM against laboratory-selected PI-resistant HIV-1 and clinical HIV-1 variants resistant to multiple FDA-approved PIs (HIVMDR). GRL-078, -079, -077, and -058 also effectively blocked the replication of HIV-1 variants highly resistant to darunavir (DRV) (HIVDRVrp51), with EC50s of 38, 62, 61, and 90 nM, respectively, while four FDA-approved PIs examined (amprenavir, atazanavir, lopinavir [LPV], and DRV) had virtually no activity (EC50s of >1,000 nM) against HIVDRVrp51 Structurally, GRL-078, -079, and -058 form strong hydrogen bond interactions between Tp-THF modified at C-5 and Asp29/Asp30/Gly48 of wild-type protease, while the P2' Cp-Abt group forms strong hydrogen bonds with Asp30'. The Tp-THF and Cp-Abt moieties also have good nonpolar interactions with protease residues located in the flap ...Continue Reading
References
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·G PantaleoA S Fauci
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N E KohlI S Sigal
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·A K GhoshJ Buthod
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·A K GhoshJ Buthod
Oct 25, 2000·Protein Science : a Publication of the Protein Society·K StrisovskyH G Kräusslich
Jul 17, 2001·The Journal of Biological Chemistry·K MaedaH Mitsuya
Jan 5, 2002·Journal of Virology·Kazuhisa YoshimuraHiroaki Mitsuya
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Terri WatkinsRonald Swanstrom
Aug 22, 2003·Organic & Biomolecular Chemistry·Ashraf Brik, Chi-Huey Wong
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Yasuhiro KohHiroaki Mitsuya
Dec 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rajesh T GandhiBruce D Walker
Apr 20, 2004·AIDS·Danuta PieniazekStefan Z Wiktor
Nov 6, 2004·The Journal of Organic Chemistry·Arun K GhoshMarcus Noetzel
Jun 3, 2006·The Journal of Infectious Diseases·Rochelle P WalenskyKenneth A Freedberg
May 16, 2007·AIDS·Constance DelaugerrePierre de Truchis
Jul 5, 2007·The Journal of Antimicrobial Chemotherapy·Nicolai LohseNiels Obel
Oct 24, 2007·The Journal of Infectious Diseases·Yumi MitsuyaRobert W Shafer
Dec 19, 2007·Advances in Pharmacology·Hiroaki MitsuyaArun K Ghosh
Feb 19, 2008·The Journal of Biological Chemistry·Jane M SayerJohn M Louis
Jan 30, 2009·Journal of Virology·Manabu AokiHiroaki Mitsuya
May 29, 2009·AIDS·Sandra De MeyerMarie-Pierre de Béthune
Sep 3, 2010·Journal of Virology·Yasuhiro KohHiroaki Mitsuya
Feb 2, 2011·Antimicrobial Agents and Chemotherapy·Kazuhiko IdeHiroaki Mitsuya
Jun 23, 2011·PLoS Medicine·Andrew EdmondsFrieda Behets
Jan 13, 2012·Infection·G SterrantinoUNKNOWN ARCA Database Study Group
Apr 18, 2012·ACS Medicinal Chemistry Letters·Arun K GhoshHiroaki Mitsuya
Sep 28, 2012·Journal of Virology·Manabu AokiHiroaki Mitsuya
Jan 4, 2013·Cold Spring Harbor Perspectives in Medicine·John Coffin, Ronald Swanstrom
Jul 24, 2013·Antimicrobial Agents and Chemotherapy·Ravikiran S YedidiHiroaki Mitsuya
Apr 18, 2014·ACS Chemical Biology·Ying ZhangIrene T Weber
Apr 18, 2014·International Journal of Nanomedicine·Maria João GomesBruno Sarmento
Nov 20, 2015·Journal of Virology·Manabu AokiHiroaki Mitsuya
Apr 20, 2016·Trends in Microbiology·Nese Kurt YilmazCelia A Schiffer
Jun 15, 2016·Journal of Medicinal Chemistry·Tanaji T Talele